HIKAL234.10

Hikal Limited

· Pharma & Health
₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,891 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity5.867.19-4.07-4.07
Return on Assets2.803.59-2.06-2.06
Return on Capital Employed8.6311.153.363.36
Return on Invested Capital5.477.071.892.04
Margins
EBITDA Margin14.9617.6612.8713.39
Operating Margin8.3710.433.303.30
Incremental Operating Margin59.2893.34
Pretax Margin5.356.66-4.57-3.33
Net Income Margin3.904.88-2.85-1.95
FCF Margin-0.987.698.998.99
Additional
Effective Tax Rate27.1226.6637.6841.52
Dvd Payout Ratio21.3116.30-25.20
Sustainable Growth Rate4.616.02-5.10-4.07
Incremental Operating Margin %59.2893.3438.39
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.